Jump to content

Stablemates Trial for NSCLC


Recommended Posts

For the first time, cancer researchers are offering patients with early stage lung cancer either surgery or stereotactic ablative radiotherapy (SABR) and comparing the results in a phase III clinical study called the Stablemates Trial.


SABR is a specialized form of radiation that has evolved in recent years to treat patients with just a few sessions – in this case just three treatments spread over eight days or less – using advanced imaging to deliver a higher dose. An early study has shown that SABR could be as effective as surgery among patients who did not qualify for surgery.


The primary objective of this study is to test the hypothesis that the 3-year overall survival in high risk operable patients with Stage I NSCLC is greater in patient who undergo SAbR as compared to standard sublobar resection (SR).


The new study now offers the same treatment to patients who are eligible for surgery but are at high risk for complications. To learn more and see a list of participating institutions, visit the trial web site.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.